Bevacizumab biosimilar - Dr. Reddy's Laboratories

Drug Profile

Bevacizumab biosimilar - Dr. Reddy's Laboratories

Alternative Names: DRL-BZ

Latest Information Update: 26 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dr Reddys Laboratories
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Colorectal cancer; Non-small cell lung cancer

Most Recent Events

  • 20 Jun 2016 Dr. Reddy's Laboratories plans a phase I pharmacokinetic trial for Cancer (in healthy volunteers) in New Zealand (ACTRN12615001204538)
  • 01 Jan 2016 Preclinical trials in Cancer in India (IV) prior to January 2016
  • 29 May 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top